

## Ethics Approval Received, New Clinical Trial Site Added

- **Northern Beaches Clinical Research (NBCR) becomes Rhythm's seventh clinical trial site involved in Study 7;**
- **NBCR network can access both private and public recruitment sites;**
- **Dr Anthony McGirr appointed as Principal Investigator; and**
- **First patient recruited.**

**27 October 2020, Melbourne:** Rhythm Biosciences Limited (ASX: RHY) is pleased to confirm that Northern Beaches Clinical Research (NBCR), based in Sydney's northern suburbs is the seventh site to join Rhythm's Clinical Trial (Study 7), the final designated trial involved in the path to initial commercialisation of RHY's ColoSTAT<sup>®</sup> test-kit, which is expected to be a globally marketed, low-cost, simple blood test for the detection of colorectal cancer, aimed at mass-market screening.

NBCR is a clinical research centre which importantly has capability to access a number of private and public recruitment sites across northern Sydney. The founders of NBCR have over 30 years of combined experience in clinical research which focuses on building a strong working relationship with its' community cohort, the clinical research organisation (CRO) and the Sponsor (RHY). Hence, they have a successful track record in delivering recruitment targets, in line with the study deadlines.

"We are excited to be partnering with Rhythm on the clinical trial of ColoSTAT<sup>®</sup>. A simple blood test like ColoSTAT<sup>®</sup> is the change the world needs both socially and economically, for colorectal cancer detection. The number of lives that could be saved with this test is significant, especially as it would significantly increase patient compliance and overall screening rates. We are excited to be a part of this journey" commented Jeff Wall, CEO of Northern Beaches Clinical Research.

"The interests of both Northern Beaches Clinical Research and Rhythm are closely aligned, not only in being committed to the best clinical outcomes but balanced with a commercial mindset to drive recruitment. The inclusion of Northern Beaches is an important step in Rhythm's strategy of engaging additional clinical sites to help accelerate patient recruitment for Study 7 after delays that have been imposed by COVID-19. We look forward to all sites building their recruitment rates and contributing strongly to what we believe will be a transformative world-leading diagnostic tool" said Rhythm CEO Glenn Gilbert.

Rhythm Biosciences continue to conduct feasibility on further sites to join the ColoSTAT<sup>®</sup> trial.

With authority of the Board.

---

**Rhythm Biosciences**

ACN: 619 459 335  
ASX: RHY

**Issued Capital**

201,495,811 Shares  
6,650,000 Options

**Australian Registered Office**

Level 2, 480 Collins Street  
Melbourne VIC 3000  
[www.rhythmbio.com](http://www.rhythmbio.com)

**Directors**

Otto Buttula – Chairman of the Board  
Trevor John Lockett – Executive Director  
Louis James Panaccio – Non-Executive Director  
David John White – Non-Executive Director  
Eduardo Vom – Non-Executive Director

For further information, please contact:

Glenn Gilbert  
Chief Executive Officer  
+61 3 8256 2880

### **About Rhythm Biosciences**

ASX-listed Rhythm Biosciences is endeavoring to develop and commercialise a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT®, is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower overall cost to public health administrations. ColoSTAT® also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT® is designed to be equipment agnostic and easily used by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT® has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.